Management of cytotoxic drug extravasation;Zytostatika-paravasation - Wie ist vorzugehen?

Krankenhauspharmazie

Volumn 23, Issue 6, 2002, Pages 261-268

  Krämer, Irene ^a   Stützle, Marion ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Antidotes; Cytotoxic drugs; Extravasation; Extravasation kit

Indexed keywords

ANTIDOTE; CYTOTOXIC AGENT;

DEVICE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG EXTRAVASATION; DRUG INDUCED DISEASE; EXTRAVASATION KIT; FIRST AID; HUMAN; REVIEW; STEM CELL TRANSPLANTATION; TISSUE INJURY;

EID: 0036079476     PISSN: 01737597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Zytostatika-paravasatc-set, vorschläge zur therapie von paravasaten
2. Zytostatika-paravasation - Wie ist vorzugehen?
3. Managing extravasations of vesicant chemotherapy drugs
4. Antidotes to vesicant chemotherapy extravasations
5. Prevention and management of antineoplastic extravasation injury
6. Systemic therapy emergencies
7. Prevention and management of extravasation of cytotoxic drugs
8. Treatment of tissue extravasation by antitumor agents
9. A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane
10. Dexrazoxane in anthracycline extravasation
11. Cutaneous and subcutaneous necrosis following dexrazoxane-CHOP therapy
12. A prospective study of topical dimethlysulfoxide for treatment anthracycline extravasation
13. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs. A prospective clinical study
14. Attenuation of dermal toxicity of doxorubicin by liposome encapsulation
15. DaunoXome® treatment of solid tumors: Preclinical and clinical investigations
16. Lack of vesicant injury following extravasation of liposomal doxorubicin
17. Gewebstoxizität und paravasatbehandlung neuer zytostatika
18. Doxil extravasation injury: A case report
19. Phase I clinical investigation of 4′-(9-acridinylami-no)methansulfon-m-anisidide (NSC 249992), a new acridine derivative
20. Mitoxantrone extravasation injury
21. Local tissue damage as a result of extravasation of mitoxantrone
22. Mitoxantrone extravasation and tissue necrosis
23. Ifosfamide extravasation
24. A model for skin toxicity of antineoplastic drugs: Doxorubicin (DOX), mitomycin-C (MMC) and vincristine (VCR)
25. Mitomycin C skin toxicity studies in mice: Reduced ulceration and altered pharmakokinetics with topical dimethylsulfoxide
26. Prevention of cytotoxic drug-induced skin ulcers with dimethylsulfoxide (DMSO) and alpha-tocopherol
27. Case Report: Topical DMSO for mitomycin C-induced skin ulceration
28. Full thickness skin necrosis due to the inadvertant interstitial infusion of cisplatin
29. Cutaneous necrosis after intraarterial treatment with cisplatin
30. Cellulitis and fibrosis due to cis-diamminedichloroplatinum II (platinol) infiltration
31. Local soft tissue toxicity following cisplatin extravasation
32. Extravasation of oxaliplatin (Eloxatin®) - Clinical course
33. Lack of toxicity in a cladribine extravasation
34. Extravasation of high-dose methotrexate: Case about nothing
35. 5-Fluorouracil extravasation following port failure
36. Inapparent infiltration associated with vindesine administration
37. Delayed treatment of vindesine extravasation
38. Vinca alkaloid skin toxicity: Antidote and drug disposition studies in the mouse
39. Antidote studies of vinorelbine-induced skin ulceration in the mouse
40. Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs
41. Empfehlungen zur behandlung von paravasaten mit vinorelbin
42. Two case reports of vinorelbine extravasation: Management and review of the literature
43. Hyaluronidase as an antidote to extravasation of vinca alkaloids: Clinical results
44. Extravasation: A hazard of intravenous therapy
45. Treatment of extravasation of both doxorubicin and vincristine administration in a Y-site infusion
46. Skin ulceration potential of paclitaxel in a mouse skin model in vivo
47. Extravasation de paclitaxel (Taxol)
48. Severe necrosis due to paclitaxel extravasation
49. Taxol-induced soft-tissue injury secondary to extravasation: Characterisation by histopathology and clinical course
50. Docetaxel extravasation: A report of five cases with treatment recommendations
51. Docetaxel-induced extravasation injury: A report of three cases
52. Docetaxel extravasation causing significant delayed tissue injury
53. Skin ulceration potential of paclitaxel in a mouse skin model in vivo
54. Clinical course and management of paclitaxel extravasation
55. Extravasation of Paclitaxel (Taxol) - Clinical course
56. Paclitaxel-induced "recall" soft tissue ulcerations occuring at site of previous subcutaneous administration of paclitaxel in low doses
57. Extravasation of topotecan: Report of two cases
58. Skin ulceration potential without therapeutic anti-cancer activity for epipodophyllotoxin commercial diluents